Structural identification of the factor XII - uPAR binding interface for selective drug development

Dillon Bohinc, B.S.
Case Western Reserve University
Cleveland, OH, U.S.

The FXII-uPAR signaling axis has been shown to upregulate neutrophil functions, which in a sterile environment, can be targeted to improve wound healing and cancer progression. Bohinc, B.S., uses this presentation to discuss the study that aimed to map the binding interface between FXII and uPAR with the goal of creating therapeutics that abrogate FXII-uPAR-mediated proinflammatory responses. Finally, the presentation concludes with the characterization and therapeutic efficacy of small molecule inhibitors that prevent FXII-uPAR effects in models of chronic inflammation, in vitro and in vivo.

Previous Article Hypoalbuminemia increases clot fibrin network density and impairs fibrinolysis during glomerular proteinuria
Next Article Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice